Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …

Background: Since disulfiram's discovery in the 1940s and its FDA approval for alcohol use
disorder, other indications have been investigated. This review describes potential clinical …

Despite several major achievements in the development of vaccines and antivirals, the fight
against SARS-CoV-2 and the health problems accompanying COVID-19 are still ongoing …

As a highly contagious human pathogen, severe acute respiratory syndrome-associated
coronavirus-2 (SARS-CoV-2) has infected billions of people worldwide with more than 6 …

There are very few small-molecule antivirals for SARS-CoV-2 that are either currently
approved (or emergency authorized) in the US or globally, including remdesivir …

A non-structural SARS-CoV-2 protein, PLpro, is involved in post-translational modifications
in cells, allowing the evasion of antiviral immune response mechanisms. In this study …

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused the
coronavirus disease 2019 (COVID-19) pandemic, posing serious threats to global health …

The SARS-CoV-2 pandemic has significantly challenged global public health, highlighting
the need for effective therapeutic options. This study focuses on the papain-like protease …

The severe acute respiratory syndrome-causing coronavirus 2 (SARS-CoV-2) papain-like
protease (PLpro) and main protease (Mpro) play an important role in viral replication events …

The spread of SARS‐CoV‐2 remains a major public health problem that threatens human
life and health. As an enveloped single‐stranded RNA virus, SARS‐CoV‐2 utilizes key …